Literature DB >> 16629619

Pharmacological approaches to repair the injured spinal cord.

Darryl C Baptiste1, Michael G Fehlings.   

Abstract

Acute traumatic spinal cord injury (SCI) results in a devastating loss of neurological function below the level of injury and adversely affects multiple systems within the body. The pathobiology of SCI involves a primary mechanical insult to the spinal cord and activation of a delayed secondary cascade of events, which ultimately causes progressive degeneration of the spinal cord. Whereas cell death from the mechanical injury is predominated by necrosis, secondary injury events trigger a continuum of necrotic and apoptotic cell death mechanisms. These secondary events include vascular abnormalities, ischemia-reperfusion, glutamate excitotoxicity and disturbances in ionic homeostasis, oxidative cell injury, and a robust inflammatory response. No gold standard therapy for SCI has been established, although clinical trials with methylprednisolone (NASCIS II and III) and GM-1 ganglioside (Maryland and Sygen) have demonstrated modest, albeit potentially important therapeutic benefits. In light of the overwhelming impact of SCI on the individual, other therapeutic interventions are urgently needed. A number of promising pharmacological therapies are currently under investigation for neuroprotective abilities in animal models of SCI. These include the sodium (Na+) channel blocker riluzole, the tetracycline derivative minocycline, the fusogen copolymer polyethylene glycol (PEG), and the tissue-protective hormone erythropoietin (EPO). Moreover, clinical trials investigating the putative neuroprotective and neuroregenerative properties ascribed to the Rho pathway antagonist, Cethrin (BioAxone Therapeutic, Inc.), and implantation of activated autologous macrophages (ProCord; Proneuron Biotechnologies) in patients with thoracic and cervical SCI are now underway. We anticipate that these studies will harken an era of renewed interest in translational clinical trials. Ultimately, due to the multi-factorial pathophysiology of traumatic SCI, effective therapies will require combined approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629619     DOI: 10.1089/neu.2006.23.318

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  79 in total

1.  The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury.

Authors:  Dong Charn Cho; Jin Hwan Cheong; Moon Sul Yang; Se Jin Hwang; Jae Min Kim; Choong Hyun Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-02-28

2.  RhoA inactivation prevents photoreceptor axon retraction in an in vitro model of acute retinal detachment.

Authors:  Aurora Maria Fontainhas; Ellen Townes-Anderson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-01       Impact factor: 4.799

3.  Kainate-mediated excitotoxicity induces neuronal death in the rat spinal cord in vitro via a PARP-1 dependent cell death pathway (Parthanatos).

Authors:  Anujaianthi Kuzhandaivel; Andrea Nistri; Miranda Mladinic
Journal:  Cell Mol Neurobiol       Date:  2010-05-26       Impact factor: 5.046

4.  Repair, protection and regeneration of spinal cord injury.

Authors: 
Journal:  Neural Regen Res       Date:  2015-12       Impact factor: 5.135

5.  Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats.

Authors:  Ihsan Anik; Sibel Kokturk; Hamza Genc; Burak Cabuk; Kenan Koc; Sadan Yavuz; Sureyya Ceylan; Savas Ceylan; Levent Kamaci; Yonca Anik
Journal:  J Spinal Cord Med       Date:  2011       Impact factor: 1.985

6.  Identification of Regeneration and Hub Genes and Pathways at Different Time Points after Spinal Cord Injury.

Authors:  Sheng Fang; An-Quan Wang; Lin Zhong; Hui Zhang; Zong-Sheng Yin
Journal:  Mol Neurobiol       Date:  2021-01-23       Impact factor: 5.590

7.  Neuronal and axonal degeneration in experimental spinal cord injury: in vivo proton magnetic resonance spectroscopy and histology.

Authors:  Junchao Qian; Juan J Herrera; Ponnada A Narayana
Journal:  J Neurotrauma       Date:  2010-03       Impact factor: 5.269

8.  The functional and neuroprotective actions of Neu2000, a dual-acting pharmacological agent, in the treatment of acute spinal cord injury.

Authors:  Joe E Springer; Ravikumar Rangaswamy Rao; Hyang Ran Lim; Sung Ig Cho; Gyoeng Joon Moon; Hee Young Lee; Eui Jin Park; Jai Sung Noh; Byoung Joo Gwag
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

Review 9.  Reorganization and preservation of motor control of the brain in spinal cord injury: a systematic review.

Authors:  Kristen J Kokotilo; Janice J Eng; Armin Curt
Journal:  J Neurotrauma       Date:  2009-11       Impact factor: 5.269

10.  Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

Authors:  Natalie E Scholpa; Hannah Williams; Wenxue Wang; Daniel Corum; Aarti Narang; Stephen Tomlinson; Patrick G Sullivan; Alexander G Rabchevsky; Rick G Schnellmann
Journal:  J Neurotrauma       Date:  2018-11-16       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.